Precision BioSciences (DTIL) Registration Filing summary

Company overview and business model

• Clinical-stage gene editing company focused on in vivo therapies for genetic and infectious diseases using the proprietary ARCUS genome editing platform, which enables precise gene edits including insertion, excision, and elimination.

• Lead programs include PBGENE-HBV, a first-in-human clinical trial for chronic Hepatitis B, and PBGENE-DMD, targeting Duchenne muscular dystrophy with an anticipated IND filing by end of 2025.

• ARCUS platform's small size allows for delivery to a broad range of cells and tissues via viral and non-viral methods.

Financial performance and metrics

• As of September 30, 2025, pro forma net tangible book value was $3.74 per share, increasing to $3.88 per share after the offering, with immediate dilution of $0.35 per share to new investors.

• Net tangible book value as of September 30, 2025, was $15.6 million, or $1.29 per share, with pro forma as adjusted net tangible book value of $143.8 million after the offering.

Use of proceeds and capital allocation

• Net proceeds from the offering will fund ongoing and planned research and development, working capital, and general corporate purposes.

• Pending use, proceeds will be invested in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit, or U.S. government obligations.